Nonalcoholic Steatohepatitis Therapeutics Market to Reach US$20.27 bn by 2025Nonalcoholic Steatohepatitis (NASH), also called the ‘silent disease,’ is a kind of fatty liver disease which typically affects people that are obese or diabetic. This disease is more prevalent in the younger generation and causes liver inflammation and/or damage owing to the accumulation of fat within the liver. The exact cause of this disease is still not clear; however, research activities are underway for finding effective treatments to cure this disease.
Transparency Market Research (TMR), a market intelligence company answers some of the chief questions that may prove helpful for companies already established in the Nonalcoholic Steatohepatitis market and also for emerging companies looking to penetrate this market.
Get Free Report Brochure PDF:http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7691
Q. Why is the treatment of NASH a prime therapeutic need?
Hepatologists have opined that NASH has emerged as a ‘ticking time bomb’ and this is why regulatory authorities such as the EMA and the FDA are supporting the requirements for the discovery of effective treatment options for curing this disease. The therapeutic needs are immense globally owing to the fact that the count of NASH cases is constantly rising, together with the obesity and diabetes epidemic. Within the U.S. alone, the prevalence of NASH is predicted to be more than 12% of the adult population.
In addition, there are a number of predictors and risk factors of NASH such as obesity, Body Mass Index (BMI), insulin sensitivity, hypertension, dyslipidemia, increase in liver enzymes, and obesity. Also, patients having NASH have an increasing risk for peripheral vascular accident or stroke and myocardial infarction.
Q. What factors will support the growth of the market for NASH therapeutics?
The rising rate of diabetes and obesity is a key factor fuelling the growth of the market. In addition, the increase in the number of clinical trials coupled with their success rate has raised the likelihood of industries receiving commercial approval for NASH therapeutics by 2017.
In addition, a number of major players are competing in the market and are conducting extensive research on therapeutics for NASH and have also received positive results from clinical trials. A recent result of a clinical trial that was conducted by Genfit satisfied the concerns of the European Medicines Agency (EMA) on the safety and efficacy of GFT505 as major therapeutics for NASH.
It was finally recommended by the EMA that the development of GFT505 as a therapeutic drug should progress to Phase III in the clinical trial. Genfit has aligned itself for registering GFT505 as the first approved therapy for NASH and this company also received a Fast Track designation on February 14, 2014 for the GFT505 NASH program.
Browse Research Release:
Q. What is the flipside or biggest challenge impacting the development of the market?
The low rate of diagnosis, the low treatment seeking rates, and the low prescription rates will continue posing a major challenge in the growth of the market particularly in the developing economies. In addition, the slow advancement of therapies for NASH and the inefficiency of diagnostic tools resulting in the delayed diagnosis of NASH may also pose a negative impact on the growth of the market.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nonalcoholic Steatohepatitis Therapeutics Market to Reach US$20.27 bn by 2025 here
News-ID: 342168 • Views: 572
More Releases from Transparency Market Research
Coronavirus's Impact On Water Analysis Instruments Market
Water analysis instruments are used to analyze water to detect the presence of hazardous chemicals and biological agents. Rising population and significant increase in rate of industrialization has increased water pollution notably which is affecting aquatic ecosystems at a global level. Ever increasing demand for safe, clean, and quality water has forced government organizations to undertake major steps against growing issues of water pollution. Water analysis instruments are used to
Digital Engineering Solutions & Services Market Huge Growth Opportunity by 2027
Digital engineering is the process of data formation, collection, and incorporation using a digital skillset. From drawings to simulation and 3D models, in a digitized world, engineers are constantly utilizing digital technology to collect data and develop design. The art of digital engineering allows designers to explore possibilities through progressive applications and develop innovative solutions in a virtual environment. Obtain Report Details @ https://www.transparencymarketresearch.com/digital-engineering-solutions-and-services-market.html Increasing usage of 3D moduling solutions 3D models are
Coronavirus's Impact On Archival Data Storage Market
Global Archival Data Storage Market: Introduction Archival data storage is a form of storage designed for data which is not needed at present but needs to be stored so that it can be retrieved in the future, if necessary. Usually, backup systems often allow for archiving records. Corporates and government organizations of various countries have started to understand the value of a secure long-term archival storage policy for their sensitive data
SIP Trunking Services Market is likely to expand swiftly, registering a strong C …
SIP (Session Initiation Protocol) Trunking Services market is set to see a steady CAGR (Compound Annual Growth Rate) of 18.6% during the forecast period 2016 to 2024, as per a Transparency Market Research (TMR) study. It would translate to market opportunities worth USD 20.75 bn. It is primarily owing to their cost benefits over traditional telephony systems. Obtain Report Details @ https://www.transparencymarketresearch.com/sip-trunking-services-market.html The use of SIP Trunking services in BFSI, Telecom
More Releases for NASH
NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
Overview of NASH - Opportunity Analysis and Forecasts to 2026
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation
Nonalcoholic Steatohepatitis (NASH) Syndrome - Opportunity Analysis and Forecast …
First described in 1980, Nonalcoholic Steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nonalcoholic Steatohepatitis (NASH) Market Worth US$ 20.0 Billion by 2025
New York, December 12: Market Research Engine has published a new report titled as “Non-Alcoholic Steatohepatitis (NASH) Market by Therapeutics (GFT505, Obeticholic Acid (INT-747), Liraglutide (Victoza) and Simtuzumab, Vitamin E, Pioglitazone, Placebo) - Global Industry Analysis, Trends and Forecast 2016 - 2025” Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025. Browse Full